Evaluation of vancomycin dosing and monitoring in adult medicine patients

Hospital Pharmacy

Volumn 47, Issue 6, 2012, Pages 451-459

  Devabhakthuni, Sandeep ^a   Gonzales, Jeffrey P ^a,b   Tata, Asha L ^a,b   Lee, Shirley ^c   Shah, Priya ^d   Offurum, Ada Ibe ^b   Gulati, Mangla ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Walgreens Pharmacy   (United States)

Author keywords

guidelines; monitoring; trough; vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; COMPUTERIZED PROVIDER ORDER ENTRY; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84861847906     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4706-451     Document Type: Article

References (17)

1. Moellering RC. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(suppl 1):S3-4.
2. Fridkin SK, Edwards JR, Pichette SC, et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis. 1999;28:1119-1125.
3. Cosgrove SE, Carroll KC, Perl TM. Staphyloccocus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004;39:539-545.
4. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
5. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575-580.
6. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521-528.
7. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(suppl 1):S13-24.
8. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylo-coccus aureus infections. Clin Infect Dis. 2002;34:1481-1490.
9. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55:240-245.
10. Thomson AH, Staatz CE, Tobin CM, et al. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63:1050-1057.
11. Karam CM, McKinnon PS, Neuhauser MM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257-266.
12. Paladino JA, Sunderlin JL, Adelman MH, et al. Observations on vancomycin use in U.S. hospitals. Am J Health Syst Pharm. 2007;64:1633-1641.
13. Rodman DP, McKnight JT, Rogers T, et al. The appropriateness of initial vancomycin dosing. J Fam Pract. 1994;38:473-477.
14. McCluggage L, Lee K, Potter T, et al. Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system. Am J Health Syst Pharm. 2010;67:70-75.
15. Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteremia. J Antimicrob Chemother. 2006;57:699-704.
16. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31:441-448.
17. Karam CM, McKinnon PS, Neuhauser NM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257-266.